"Microtubule-stabilizing agents are among the most important drugs available
for the treatment of cancer, and the development of useful new agents in this
class is an important goal to increase therapy options for cancer patients.reatapharma. BOSTON, Surface Logix is pleased to announce the
appointment of Dr. "Warwick's medical
background combined with his 12 years of broad pharmaceutical industry
experience in commercial and clinical development brings a valuable mix of
skills and experience to our company as we take our first drugs into clinical
development .

wellington auckland

We are pleased to be collaborating with UT Southwestern and Victoria
University in the further development of these promising drugs. "These agreements are a major step in the development of
Peloruside A towards realizing the exciting promise it has already shown in
research carried out in New Zealand . "It creates real value for all parties, and
more importantly, serves as the springboard for the development of an
important new anticancer agent that can benefit mankind. Warwick Tong as Senior Vice President, Commercial
Development.

anthropology hamilton

social department

("Reata") announced the completion of a license
agreement with The University of Texas Southwestern Medical Center at Dallas
("UT Southwestern") and Victoria University of Wellington, New Zealand ("VU"),
providing Reata with exclusive worldwide rights to a promising new class of
anticancer compounds. The company's
most advanced products, RTA 744 for primary brain cancer and RTA 401 (CDDO)
for hematological cancers and solid tumors, are expected to enter clinical
trials in mid-2005. Tong will primarily be
responsible for driving the commercial input into the selection and direction
of the drug development programs at Surface Logix.

palmerston science

DALLAS and WELLINGTON, New Zealand, Reata
Pharmaceuticals, Inc. However, research at Reata , VU and UT Southwestern has
shown that it binds to a distinct target site on the tubulin molecule and
retains potent activity in cells that are highly resistant to paclitaxel and
several other drugs in the class.

zealand palmerston

Dr Tong originally
joined Glaxo in New Zealand as a Medical Director after a number of years in
clinical medicine with interests in primary care and drug dependency.

social wellington

I look forward to working with him as we build on the success of our
Pharmacomer(TM) Technology Platform and push forward into the clinic with the
drug development programs that have resulted from the application of this
technology," said Jim Mahoney, CEO of Surface Logix."
Prior to Surface Logix, Dr.

anthropology new

Reata Announces Licensing of Novel Natural Products With Anticancer Potential; Discovered at Victoria University First Synthesized at UT Southwestern

The company has initiated a preclinical development
program with peloruside A, the first identified compound in the class, which
could enter clinical testing as early as 2007. Surface Logix has
several drugs in clinical and preclinical development .

wellington hamilton

The compound was later
patented in the United States by Victoria Link Ltd."
Reata Pharmaceuticals , Inc. As a member of the executive team, Dr.
Dr.

wellington policy

For more information, please see http://www. Previously, Dr Tong led the global commercial strategy
group for anti-infectives in Glaxo Wellcome following a period as the Regional
Business Development Director for the Asia Pacific Region .

massey policy

anthropology auckland

Anderson Cancer Center, Dartmouth College, Victoria University
of Wellington, New Zealand , and the National Cancer Institute.
"I am extremely pleased to welcome Warwick to the Surface Logix executive
team. Tong worked as Vice President, Strategy and
Redesign with GlaxoSmithKline , leading a major redesign program in the late
stage development organization following the merger of Glaxo Wellcome and
Smith Kline Beecham.

auckland victoria

Peloruside A was first
discovered in a marine sponge , part of the diverse and often unique indigenous
bioata residing in New Zealand's Pelorus Sound.

Tong received his medical degree (MB ChB) from Auckland University
Medical School in New Zealand and has a Masters in Public Policy from Victoria
University in Wellington, New Zealand.com.

new cultures

"These exciting compounds are an important component of the Reata product
pipeline," said Warren Huff, President and Chief Executive Officer of Reata."
"This three-way agreement illustrates the importance of global
collaboration in creating new pharmaceutical products, and it also exemplifies
the crucial role university research plays in the process leading to new
clinical advances," said Dr.

Surface Logix Appoints Senior VP of Commercial Development

The company uses its
proprietary small molecule Pharmacomer(TM) Technology to chemically modify
drugs and late stage compounds to create New Chemical Entities (NCEs) with
improved bioavailability and tissue distribution profiles .

policy sciences

Peloruside A, which has potent anticancer activity in a variety of cancer
types, acts on microtubules, a target addressed by paclitaxel and other major
anticancer drugs."
Victoria University's Dean of Science, Professor David Bibby, welcomed the
agreements.
Surface Logix is a drug development company that creates new therapeutics
by significantly improving the pharmacokinetic (PK) and pharmacodynamic (PD)
properties of approved drugs and late stage compounds.

new anthropology

Subsequently , researchers at UT Southwestern achieved the
first total synthesis of this complex molecule.com .

massey wellington

Dennis Stone, vice president for technology
development at UT Southwestern.surfacelogix.

Sociology department websites in New Zealand.

departments cultures

is a development-stage company focused on the
development of novel treatments for cancer, inflammation, and
neurodegenerative diseases.

cultures science

science massey

It is a significant step to move forward in association with the prestigious
University of Texas Southwestern Medical Center at Dallas and Reata
Pharmaceuticals. Founded in 2002, Reata is developing five
distinct classes of cancer drugs licensed from UT Southwestern, The University
of Texas M. Clinical testing of additional products, including RTA
402 for inflammation, is expected to begin in late 2005 or early 2006.

websites sociology

"
Professor Bibby emphasized that "although the development of Peloruside A
was first supported by substantial grants from New Zealand, international
links were now needed to further progress the development to clinical trials.

victoria christchurch

, the University's
commercial arm. Tong will also help
drive key business relationships with thought leaders and potential partners
in the therapeutic areas of interest for the company. Surface Logix also
combines its Pharmacomer(TM) Technology with nanotechnology capabilities to
create miniaturized assays to test the interaction of biological molecules
with potential drug candidates.

science university

websites waikato

Reata
is also using a proprietary drug screening platform to identify potential
breakthrough treatments for cancer and neurodegenerative diseases such as ALS
(Lou Gehrig's disease) and Alzheimer's disease. Dr. These assays serve as ex-vivo models to
evaluate and fine-tune the oral bioavailability, membrane permeability,
metabolism, and distribution characteristics of NCEs. For more information on
our programs please visit our website at http://www.